Influenza and pneumococcus vaccination: current recommendations by Ceyhan, Berrin
Marmara Medical Journal 2016; 29 (Special issue 2): 26-31
DOI: 10.5472/MMJsi.2902.07
   REVIEW ARTICLE
26
ABSTRACT
Acute asthmatic exacerbation and hospital admission may be 
associated with severe influenza infection. It has been reported 
that immunization with inactivated influenza vaccine in patients 
with persistent asthma decreased respiratory illnesses and asthma-
related events. Evidence from more recently published randomized 
trials indicated that there is no significant increase in asthma 
exacerbations immediately after influenza vaccination. Similarly, 
inactivated influenza vaccine in chronic obstructive pulmonary disease 
(COPD) patients resulted in a significant reduction in the total number 
of exacerbations when compared with placebo. The highest incidence 
of invasive pneumococcal disease occurs in children <5 years of age, 
immunocompromised persons such as HIV, and those ≥65 years of 
age. Therefore, pneumococcal vaccine has been recommended for 
all adults ≥65 years of age and in younger patients who have a 
condition that increases the risk of invasive pneumococcal disease 
or pneumococcal pneumonia. The development of pneumococcal 
conjugate vaccines represents a major advance, and the use of such 
vaccine has reduced the incidence of pneumococcal disease and 
acute exacerbation in COPD patients. There are limited data about 
the effect of pneumococcal vaccine on asthmatic patients. 
Keywords: Influenza vaccine, Pneumococcal vaccine, Asthma, 
COPD
Seasonal influenza vaccination in adults
Influenza virus may result in an acute respiratory illness. 
There are two types of viruses as influenza A and B. 
Influenza epidemics are reported nearly every year and the 
risk is highest in the winter season. Influenza vaccines are 
developed to prevent influenza infection in the population. 
Scientific researchers reported that influenza viruses 
change their antigenic characteristics frequently. Therefore, 
annual influenza vaccination should be redeveloped against 
these novel antigens [1-4]. The United States Centers for 
Disease Control and Prevention (CDC) and the World 
Health Organization (WHO) held a worldwide network to 
track influenza virus isolates every year and to predict the 
appropriate annual influenza vaccine type. New vaccines are 
produced each year to match viruses over world. Influenza A 
viruses show periodic changes in the antigenic characteristics 
of their envelope glycoproteins, the hemagglutinin and the 
neuraminidase [5]. Major changes of glycoproteins are called 
as antigenic shifts and minor changes as antigenic drifts and 
also antigenic drifts in the hemagglutinin have been reported. 
Ongoing studies screen these changes annualy to produce 
the well matched vaccines. Current influenza vaccines are 
trivalent or quadrivalent [4]. The trivalent vaccine contains 
two influenza A virus antigens and one influenza B virus 
antigen, the quadrivalent vaccine contains two influenza 
A antigens and two influenza B antigens. A quadrivalent 
formulation is favored over a trivalent formulation when 
possible. Annual immunization is recommended even if 
the previous year’s vaccine contained same virus antigen 
because immunity declines gradually over time. In a meta-
analysis, the overall efficacy of inactivated vaccines in 
preventing laboratory-confirmed influenza was 60% in 
2014 (53 to 66 %) [6]. Commercially, two different types of 
influenza vaccine are available, inactivated influenza vaccine 
(IIV) and live-attenuated influenza vaccine (LAIV) [2,4]. 
The available inactivated trivalent or quadrivalent influenza 
vaccines are prepared by split virion or subunit vaccines 
that have been inactivated. The standard-dose of inactivated 
influenza vaccines are usedintramuscularly in adults of any 
age. These vaccines are produced in embryonated chicken 
eggs. Standard-dose quadrivalent LAIV is administered 
intra nasally and is approved for healthy non-pregnant 
adults up to 49 years of age. Comparisons of inactivated and 
live-attenuated vaccines have shown that the differences 
between the two vaccines were not statistically significant. 
In this field, there are numerous studies to develop new 
vaccines with high efficiency and efficacy. Recently, a 
vaccine using recombinant DNA technology was approved 
in USA. Currently, vaccine production takes six months 
from the selection of virus type until production. A single 
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dose of an influenza vaccine should be offered soon after 
the vaccine becomes available, ideally by October in the 
northern hemisphere and May in the southern hemisphere. 
Influenza virus usually causes an acute self-limited illness 
in healthy young adults, however, older adults and patients 
with different health problems are high risk groups [7,8]. 
The United States Advisory Committee on Immunization 
Practices (ACIP) expanded the recommendation for 
influenza vaccination to include all individuals six 
months of age and older. Annual influenza vaccination is 
recommended for healthy non-pregnant adults <65 years of 
age (Grade 1A). Studies revealed Grade 1B for individuals 
≥65 years of age and for other individuals at increased risk 
for severe influenza (eg, immunocompromised; chronic 
cardiovascular, pulmonary, or metabolic disease, renal, 
hepatic, hematologic diseases (including sickle cell disease), 
pregnancy, obesity, neuromuscular and neurodevelopmental 
disease, chronic aspirin use, resident of nursing home).
Healthcare personnel and household contacts or 
caregivers of persons with medical conditions should remain 
high priority for vaccination. Since influenza infection is 
associated with excess complications and death in pregnant 
women, influenza vaccine is recommended for pregnant 
women with any trimester and women who might be 
pregnant during the influenza season [2].
For individuals ≥65 years of age, the high-dose inactivated 
influenza vaccine is favored when available rather than a 
standard-dose inactivated influenza vaccine. The studies 
reported that high-dose vaccine is more immunogenic and 
more effective than the standard-dose vaccine in older 
patients (Grade 2B). 
In a Cochrane meta-analysis, the vaccines were 58% 
percent effective against influenza in older patients [9]. In 
the 2012 to 2013 influenza season, influenza vaccine had 40 
percent effectiveness and decreased approximately 60,000 
hospitalizations among individuals ≥65 years of age in 
the United States [10]. There is a small number of studies 
evaluating mortality as an endpoint. A small but significant 
reduction in mortality in vaccinated older individuals was 
reported in a cohort study [11].
Co vaccination is an important point, inactivated influenza 
vaccines do not interfere with the other inactivated or live virus 
vaccines [2,12]. LAIV can also be administered at the same 
time with other inactivated vaccines [13]. However it should 
be administered at least four weeks after live virus vaccines. 
If possible, individuals on statins should receive the high-dose 
vaccine, since statins may decrease vaccine responses. 
Table I. For 2015–16, ACIP recommends the followings for 
influenza vaccination [14]:
1. All persons aged ≥6 months should receive influenza vaccine 
annually. 
2. For healthy children aged 2 through 8 years who have no 
contraindications or precautions, either LAIV or IIV is an 
appropriate option. LAIV should not be used in the following 
populations:
• Persons aged <2 years or >49 years
• Persons with contraindications listed in the package insert:
o Children aged 2 through 17 years who are receiving 
aspirin or aspirin-containing products
o Persons who have experienced severe allergic reactions 
to the vaccine or any of its components, or to a previous 
dose of any influenza vaccine
• Pregnant women
• Immunocompromised persons 
• Persons with a history of egg allergy
• Children aged 2 through 4 years who have asthma or who 
have had a wheezing episode noted in the medical record 
within the past 12 months, or for whom parents report that 
a health care provider stated that they had wheezing or 
asthma within the last 12 months.
• Persons who have taken influenza antiviral medications 
within the previous 48 hours.
3. In addition to the groups for whom LAIV is not recommended 
above, the “Warnings and Precautions” section of the LAIV 
package insert indicates that persons of any age with asthma 
might be at increased risk for wheezing after administration of 
LAIV. The package insert also notes that the safety of LAIV in 
persons with other underlying medical conditions that might 
predispose them to complications after wild-type influenza 
virus infection (e.g., chronic pulmonary, cardiovascular [except 
isolated hypertension], renal, hepatic, neurologic, hematologic, 
or metabolic disorders [including diabetes mellitus]), has not 
been established. These conditions, in addition to asthma in 
persons aged ≥5 years, should be considered precautions for 
the use of LAIV.
4. Persons who care for severely immunosuppressed persons who 
require a protective environment should not receive LAIV, or 
should avoid contact with such persons for 7 days after receipt, 
given the theoretical risk for transmission of the live attenuated 
vaccine virus to close contacts.
Seasonal influenza vaccination in patients with asthma 
or COPD
Influenza in asthmatic patients is associated with increased 
health care services use (hospital admissions, clinic visits, 
and emergency department visits). Inactivated influenza 
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vaccine in patients with persistent asthma resulted in 
decreased respiratory illnesses and asthma-related events. In 
a Cochrane review, the controlled trials noted no benefit in 
preventing influenza-related asthma exacerbations, although 
vaccination might improve specific aspects of asthma-
related quality of life among children. Moreover, it has been 
shown that IIV is not associated with asthma exacerbations 
2 weeks after vaccination in children and adults [15]. A 
few studies support the hypothesis that IIV vaccination 
might provide protection against influenza-related asthma 
exacerbations, but these studies were not prospective, 
randomized, or controlled and thus were excluded from 
analysis in the Cochrane review [15]. A study noted that 
vaccination was associated with reduced oral steroid use 
for asthma exacerbations and a protective effect in reducing 
severity-adjusted asthma exacerbations by 22% to 45% [16-
18].
In patients with COPD, the influenza vaccine annually 
is recommended to prevent acute exacerbations of COPD 
(Grade 1B) [19]. In COPD patients, the influenza vaccine 
effectiveness was up to 76%. Several observational studies 
showed a reduction in the number of hospitalizations, 
incidence of pneumonia, risk of death, and number of 
acute exacerbations in COPD patients who received 
the influenza vaccine. Wongsurakiat and colleagues 
described the protective effects of a trivalent split-virus 
vaccine in patients with COPD by analyzing the number 
and severity of episodes of total acute respiratory illness. 
They found that the overall incidence of influenza-related 
respiratory infection in the vaccinated group was less than 
one fourth that in the placebo group. The effectiveness of 
vaccination was not influenced by the severity of COPD 
[20]. 
Pneumococcal vaccination in adults
Pneumococcal infections, including pneumonia and 
invasive disease such as bacteremia and meningitis may 
result in high risk of morbidity and mortality in children <5 
year of age, older adults, and persons immunocompromised. 
The surface capsular polysaccharide of Streptococcus 
pneumoniae is the main part for production of antibody 
against bacteria. Pneumococcal vaccines are produced 
using some of these 90 different pneumococcal capsular 
serotypes that are identified as causative agent for invasive 
disease. Pneumococcal vaccination is recommended for all 
children, for adults who have high risk for pneumonia or 
invasive pneumococcal disease, and for all adults ≥65 years 
of age (Grade 1B). Pneumococcal vaccine is recommended 
especially for following patients [21-23] (Table II).
Table II. High risk groups for pneumococcal vaccination in adults
Chronic lung disease
Chronic heart disease
Diabetes Mellitus
Cerebrospinal fluid leaks
Cochlear implant
Functional or anatomic asplenia
Cigarette smoking
Aged≥ 65
Sickle cell disease/other hemoglobinopathies
Congenital or acquired immunodeficiency
Chronic renal failure
Nephrotic syndrome
Leukemia/lymphoma
Hodgkin disease
Generalized malignancy
Solid organ transplant
Diseases associated with treatment with immunosuppressive drugs 
or radiation therapy
Two types of pneumococcal vaccines are approved. 
Pneumococcal polysaccharide vaccine (PPSV23) consists 
of capsular material from 23 pneumococcal types. 
Pneumococcal conjugate vaccine (PCV) initially marketed 
as a 7-valent vaccine, now PCV13 consists of capsular 
polysaccharides from the 13 most common types that cause 
disease; it is covalently linked to a nontoxic protein to increase 
the immunologic response. PCV13 is recommended for all 
adults ≥65 years of age. United States Advisory Committee 
on Immunization Practices (ACIP) recommended sequential 
administration of both PCV13 and PPSV23 [21-23]. In 
accordance with the ACIP, PPSV23 is recommended alone 
for persons aged 19 to 64 years who have certain risk factors 
for pneumococcal infection and/or serious complications of 
pneumococcal infection [21-23]. The ACIP recommends 
that both PCV13 and PPSV23 be given sequentially to all 
adults aged ≥65 years and to adults of any age who have the 
underlying conditions listed above. When possible, PCV13 
should be given first, followed by PPSV23 [21-23] as shown 
in Fig 1.
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Fig 1. Recommendation of ACIP on intervals between PCV13 and 
PPSV23 Vaccines (2015).
These pneumococcal vaccines may be given concomitantly 
with other vaccines. Concurrent use of PPSV23 with the 
influenza vaccine is safe and does not alter the effectiveness 
of either vaccine. At the present time, revaccination of adults 
with PCV13 is not recommended.
Many studies of the pneumococcal polysaccharide 
vaccine have demonstrated efficacy against invasive and 
noninvasive pneumococcal disease such as bacteremia and 
meningitis, but both immunogenicity and efficacy are lower 
in elderly patients and immunocompromised hosts [24]. 
The CAPiTA trial, a randomized placebo-controlled trial 
that included approximately 85,000 adults ≥65 years of age 
in the Netherlands between 2008 and 2010 and who had 
not received a pneumococcal vaccine previously. The trial 
demonstrated 46 percent efficacy of PCV13 against vaccine-
type pneumococcal pneumonia, 45 percent efficacy against 
vaccine-type non-bacteremic pneumococcal pneumonia, 
and 75 percent efficacy against vaccine-type invasive 
pneumococcal disease [25]. 
Several case-control studies, randomized trials, and meta-
analyses have shown that the pneumococcal polysaccharide 
vaccine (PPSV) prevents pneumococcal disease. However, 
other published studies have failed to demonstrate efficacy 
for preventing invasive or noninvasive disease [26] or for 
reducing mortality [27, 28]. A 2013 systematic review 
and meta-analysis showed PPSV prevented invasive 
pneumococcal disease, all-cause pneumonia, but not all-
cause mortality in adults in 16 randomized trials [27]. 
Pneumococcal vaccine in patients with asthma or COPD
Pneumococcus colonization occurs more frequently in 
the airways of patients with COPD when compared to 
healthy controls. It is associated with a higher risk of 
COPD exacerbation. Patients with chronic respiratory 
disease (COPD, chronic bronchitis and/or asthma) are at 
a higher risk of pneumonia than individuals without these 
comorbidities. Risk of pneumonia increases with age. 
Among individuals with COPD, those aged 65–79 or ≥80 
years have an increasingly higher risk than those aged 
45-65 years [29]. Having COPD, and greater age, lack of 
pneumococcal vaccination, and corticosteroid therapy have 
been identified as independent risk factors for recurrent 
community acquired pneumonia (CAP) in adults [30]. 
Therefore, pneumococcal vaccine is recommended as part of 
overall medical management in patients with COPD (Grade 
2C). Centers for Disease Control and Prevention (CDC) 
and World Health Organization (WHO) recommended the 
use of pneumococcal vaccine for all adults aged ≥ 65 years 
and those aged 19 to 64 years with underlying medical 
conditions such as COPD [31]. Several retrospective studies 
showed a reduction in incidence of community-acquired 
pneumonia, hospitalizations, as well as prevention of 
invasive disease [32, 33]. However, a 2008 Cochrane review 
of adults found a reduction in invasive pulmonary disease 
after pneumococcal vaccination but no reduction in all-
cause pneumonia and mortality [34]. Moreover, two studies 
in Japan showed a reduction in bacterial infections and acute 
exacerbations of COPD in subjects receiving both influenza 
and pneumococcal vaccines when compared to either alone 
[35, 36].
There are limited data available for the role of PPSV23 in 
asthma. The positive association between asthma and risk of 
invasive pulmonary disease supports the addition of asthma as 
a high-risk condition for pneumococcal vaccination. A 2002 
Cochrane review found only one study of PPSV23 and 
asthma which met their entry requirement for review. This 
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study found a reduction in the number of acute exacerbations 
following PPSV23 vaccination; however, a study by Lee 
et al. found no significant difference in the relative risk 
of hospitalization due to pneumococcal pneumonia after 
PPSV23 in patients with asthma compared to controls 
[32,37]. Despite these discrepancies, ACIP and CDC 
recommend pneumococcal and influenza vaccination for all 
adults with asthma, COPD, and cigarette smokers [38].
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